Drug intelligence / Profile preview

placebo + citalopram

Development stage: Unknown
Lead developer: Allergan
Modality: Small Molecules
Administration: Oral

Overview

This refers to the combination of citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, administered together with a placebo. In clinical trials, this typically means patients receive active citalopram alongside an inert substance (placebo) for comparison or blinding purposes. Citalopram acts by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and improving mood symptoms in conditions such as major depressive disorder. The combination is not a marketed pharmaceutical product but rather a research protocol used to assess efficacy and safety of citalopram versus other treatments or combinations[4][5].

Other names: placebo plus citalopramcitalopram with placebo

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on placebo + citalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + citalopram.

Explore the full profile